^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    Monjuvi (tafasitamab-cxix) (CD19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Morphosys Press Release
    Title:

    Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Published date:
    08/24/2021
    Excerpt:
    MorphoSys AG: today announced that Health Canada has granted Incyte, its development and commercialization partner for tafasitamab, a Notice of Compliance with conditions for Minjuvi(R) (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)...
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    07/31/2020
    Excerpt:
    MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    Morphosys Press Release
    Title:

    MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL

    Published date:
    08/26/2021
    Excerpt:
    MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/13/2020
    Excerpt:
    Diffuse Large B-Cell Lymphoma…Other recommended regimen, "Tafasitamab + lenalidomide" was added as a category 2A recommendation.